Aveanna Healthcare (NASDAQ:AVAH) CEO Sells $226,373.32 in Stock

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) CEO Jeff Shaner sold 27,674 shares of the company’s stock in a transaction on Wednesday, December 31st. The stock was sold at an average price of $8.18, for a total transaction of $226,373.32. Following the sale, the chief executive officer directly owned 2,423,536 shares in the company, valued at $19,824,524.48. This trade represents a 1.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Jeff Shaner also recently made the following trade(s):

• On Friday, January 2nd, Jeff Shaner sold 29,357 shares of Aveanna Healthcare stock. The stock was sold at an average price of $7.85, for a total transaction of $230,452.45.
• On Tuesday, December 30th, Jeff Shaner sold 27,929 shares of Aveanna Healthcare stock. The shares were sold at an average price of $8.36, for a total transaction of $233,486.44.

Aveanna Healthcare Trading Down 1.1%

Aveanna Healthcare stock opened at $8.08 on Monday. The stock has a 50-day simple moving average of $8.92 and a 200 day simple moving average of $7.52. The stock has a market capitalization of $1.69 billion, a P/E ratio of 22.44 and a beta of 2.06. The company has a debt-to-equity ratio of 140.39, a quick ratio of 1.23 and a current ratio of 1.23. Aveanna Healthcare Holdings Inc. has a 52 week low of $3.67 and a 52 week high of $10.32.

Aveanna Healthcare (NASDAQ:AVAH) last released its quarterly earnings data on Monday, May 22nd. The company reported $0.04 earnings per share (EPS) for the quarter. Aveanna Healthcare had a negative return on equity of 143.55% and a net margin of 3.29%.The company had revenue of $450.53 million during the quarter. Analysts expect that Aveanna Healthcare Holdings Inc. will post -0.06 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on AVAH shares. Zacks Research cut shares of Aveanna Healthcare from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 20th. JPMorgan Chase & Co. upgraded shares of Aveanna Healthcare from an “underweight” rating to a “neutral” rating and raised their price objective for the stock from $6.00 to $10.00 in a research report on Thursday, September 18th. William Blair assumed coverage on Aveanna Healthcare in a report on Monday, December 8th. They set an “outperform” rating for the company. Truist Financial increased their target price on Aveanna Healthcare from $9.50 to $10.00 and gave the stock a “hold” rating in a research note on Friday, November 7th. Finally, BMO Capital Markets started coverage on Aveanna Healthcare in a report on Thursday, November 13th. They set an “outperform” rating and a $11.00 price target for the company. Five investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, Aveanna Healthcare currently has an average rating of “Hold” and a consensus price target of $10.69.

Institutional Investors Weigh In On Aveanna Healthcare

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Dynamic Technology Lab Private Ltd boosted its stake in shares of Aveanna Healthcare by 8.9% in the third quarter. Dynamic Technology Lab Private Ltd now owns 14,149 shares of the company’s stock valued at $126,000 after buying an additional 1,151 shares during the period. Barclays PLC increased its stake in Aveanna Healthcare by 0.8% during the 3rd quarter. Barclays PLC now owns 179,359 shares of the company’s stock worth $1,591,000 after acquiring an additional 1,366 shares during the period. Franklin Resources Inc. raised its holdings in Aveanna Healthcare by 4.5% in the 3rd quarter. Franklin Resources Inc. now owns 35,630 shares of the company’s stock valued at $316,000 after acquiring an additional 1,528 shares in the last quarter. Olympiad Research LP lifted its position in shares of Aveanna Healthcare by 7.5% during the 3rd quarter. Olympiad Research LP now owns 31,621 shares of the company’s stock valued at $280,000 after acquiring an additional 2,200 shares during the period. Finally, Rhumbline Advisers grew its holdings in shares of Aveanna Healthcare by 4.0% during the 1st quarter. Rhumbline Advisers now owns 75,581 shares of the company’s stock worth $410,000 after purchasing an additional 2,918 shares in the last quarter. 87.96% of the stock is currently owned by institutional investors and hedge funds.

Key Aveanna Healthcare News

Here are the key news stories impacting Aveanna Healthcare this week:

• Negative Sentiment: CEO Jeff Shaner sold multiple blocks (roughly 83,000+ shares across Dec. 30–Jan. 2 in the filings), at prices around $8.18–$8.36, reducing his stake by about 1–1.2% in individual trades while retaining a multi‑million‑share holding — investors may view repeated CEO sales as a negative signal. SEC filing — Jeff Shaner
• Negative Sentiment: CFO Matthew Buckhalter executed several sales (totaling ~70,000+ shares across Dec. 30–Jan. 2) at roughly $7.85–$8.36, each reducing his position by ~3.5–4%. Repeated CFO sales can raise governance/comfort concerns for short‑term holders. SEC filing — Matthew Buckhalter
• Negative Sentiment: CAO Deborah Stewart sold multiple blocks (~34,000+ shares across Dec. 30–Jan. 2) at similar price levels, trimming her stake by ~4% in reported trades while keeping a substantial holding — another senior exec sale that may pressure sentiment. SEC filing — Deborah Stewart
• Negative Sentiment: Insider Edwin C. Reisz sold multiple tranches (~51,000+ shares across Dec. 30–Jan. 2) at $7.85–$8.36, reducing his position by ~1.2% in several filings. Multiple insider sellers across ranks amplify negative interpretation. SEC filing — Edwin C. Reisz
• Negative Sentiment: Insider Patrick A. Cunningham reported several sales (~36,000+ shares across Dec. 30–Jan. 2) at similar price points, lowering his stake by ~3.6–4.1% in the disclosed trades. Collective insider selling increases perceived supply risk. SEC filing — Patrick A. Cunningham

About Aveanna Healthcare

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.